Project Grant R01AI180451
- This $489,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research grant program (CFDA 93.855), supports research to overcome technical obstacles in understanding the assembly and regulation of B cell antigen receptors (BCRs). The award aims to develop effective adaptive immunity following infection and vaccination by engineering appropriate cell lines and utilizing native membrane environments to study BCR...
- This $556,843 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of the extrafollicular (EF) B cell response and its role in immunity. The project aims to investigate how the EF response, which produces rapid expansion and differentiation of plasma cells, differs from the more well-studied germinal center (GC) response. Key focus...
- This Project Grant award, valued at $778,829.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Emory University. The grant supports research to characterize early-life B-cell and antibody-secreting cell (ASC) development and function, with the goal of uncovering the mechanisms of adaptive immunity at birth. The research aims to validate previous findings on the role of the spleen in...
- The National Science Foundation (NSF) Division of Emerging Frontiers awarded a $613,690 Project Grant to the University of Rochester to investigate the evolution of immune investment strategies across amphibian ontogeny. The project, titled "Collaborative Research: INTBIO: The Evolution of Immune Investment Strategies Across Amphibian Ontogeny," falls under NSF's Biological Sciences (CFDA 47.074) program, which supports basic research to strengthen the nation's scientific enterprise....
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to define the role of the NF-κB signaling network in regulating affinity maturation and the generation of plasma cells versus memory B cells. The $625,348 grant, awarded to the University of Utah, aims to elucidate how the NF-κB regulators IκBα and IκBε control the differentiation of germinal center B cells into long-lived plasma cells...
- This Project Grant award from the National Science Foundation (NSF) under the Mathematical and Physical Sciences (CFDA 47.049) Federal Grant Program provides $599,999 to Duke University for a project titled "Challenges in Stochastic Modeling and Computation for Sequential Vaccine Design." The project aims to address technical challenges in computational modeling of the stochastic immune system in order to improve methods for estimating the probability of inducing broadly protective...
- This National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) Project Grant award of $372,060 to the Research Foundation of the City University of New York (RFCUNY) - Brooklyn College will support research comparing the immune system structure, function, and memory in animal species with and without intact adaptive immune systems. The 3-year project aims to use single-cell RNA sequencing, immunization experiments, and pathogen exposure to better understand the evolutionary...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to President and Fellows of Harvard College, doing business as Harvard Medical School. The $167,915 grant, effective from February 1, 2025 to September 29, 2027, will support research to define how B cell receptor binding site copy number at the cell surface is developmentally regulated to optimize antigen recognition and support...
- This Project Grant award from the National Science Foundation (NSF) Division of Emerging Frontiers, under the Biological Sciences program (CFDA 47.074), provides $388,992 to the University of Central Florida (UCF) to investigate the evolution of immune strategies across amphibian ontogeny. The key objectives are to: (1) use mathematical models and empirical data to predict when evolutionary history, pathogens, and environment favor T cell diversity within and among amphibian life stages; (2)...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
INFERRING THE RULES OF ANTIBODY EVOLUTION USING REPLICATED GERMINAL CENTERS - PROJECT SUMMARY GERMINAL CENTERS (GCS) ARE THE SITE OF AFFINITY MATURATION, A PROTOTYPICAL DARWINIAN PROCESS THAT IS REQUIRED TO GENERATE THE POTENT ANTIBODIES THAT PROTECT AGAINST INFECTIOUS DISEASE. OVER THE PAST DECADES, WORK BY SEVERAL GROUPS, INCLUDING OUR OWN, HAS LED TO A COMPREHENSIVE GENERAL UNDERSTANDING OF THE CELLULAR AND MOLECULAR MECHANISMS THAT DRIVE EVOLUTION IN THE GC. HOWEVER, THIS MECHANISTIC UNDERSTANDING HAS YET TO REACH SUFFICIENT GRANULARITY TO ALLOW FOR ACCURATE PREDICTION OF THE OUTCOMES OF GC EVOLUTION AND EFFICIENT GUIDANCE OF GC B CELLS ALONG PREDETERMINED MUTATIONAL TRAJECTORIES. SEVERAL POPULATION-LEVEL PHENOMENA OBSERVED IN GCS REMAIN POORLY UNDERSTOOD, INCLUDING THE APPARENT STOCHASTICITY OF "CLONAL BURSTS," PROLIFERATIVE SPREES IN WHICH THE ENTIRE GC IS TAKEN OVER BY THE DESCENDANTS OF A SINGLE CELL IN A MATTER OF A FEW DAYS, THE CONTINUOUS PRESENCE OF B CELLS WITH LOW AFFINITIES IN GCS EVEN AT LATE STAGES OF THE REACTION, AND THE APPARENT INABILITY OF GCS TO FIND CERTAIN SOMATIC MUTATIONS DESPITE THEIR BENEFIT IN TERMS OF AFFINITY. GREATER UNDERSTANDING OF THESE APPARENTLY ABERRANT EVOLUTIONARY PATHWAYS MAY IMPROVE OUR ABILITY TO PREDICT AND POTENTIALLY CONTROL THE OUTPUT OF THE GC REACTION. IN THIS APPLICATION, WE DEVELOP A FULL TOOLSET CONSISTING OF A MOUSE MONOCLONAL FORGENES ENCODING AN ANTIBODY TO A CLASSIC PROTEIN ANTIGEN, A DEEP MUTATIONAL SCAN (DMS) EXPERIMENT IN WHICH THE EFFECTS ON AFFINITY OF EVERY POSSIBLE MUTATION IN BOTH CHAINS OF THISARE MEASURED EXPERIMENTALLY, AND A COMPUTATIONAL FRAMEWORK THAT ALLOWS US TO ASSIGN AFFINITIES TO ANYSEQUENCE THAT WE RECOVER FROM THESE MONOCLONAL GC B CELLS. WE WILL USE THESE TOOLS TO CONDUCT REPLICATED EVOLUTION EXPERIMENTS ON HUNDREDS OF GCS, RECONSTRUCTING THE EVOLUTIONARY PATHS AND AFFINITIES OF THOUSANDS OF B CELLS IN THE COURSE OF GC MATURATION. WE PROPOSE TO USE THIS APPROACH TO GAIN INSIGHT INTO HOW B CELL EVOLUTION PLAYS OUT WITHIN GCS IN VIVO, FOCUSING ON THE INTERPLAY BETWEEN REPRODUCIBILITY AND STOCHASTICITY IN EVOLUTION. UNDERSTANDING SUCH EVOLUTIONARY ASPECTS WILL BE IMPORTANT FOR THE FIELD'S EFFORTS TO GUIDE B CELL CLONES THROUGH DEFINED AFFINITY MATURATION TRAJECTORIES THROUGH VACCINATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $812.4k | 5/7/25 | ||
| Not listed | $81.2k | 9/5/24 | ||
| Not listed | $81.2k | 9/5/24 | ||
| Not listed | $0 | 8/1/24 | ||
| Not listed | $0 | 8/1/24 |